ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: capecitabine
Drug: oxaliplatin
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: reverse transcriptase-polymerase chain reaction
Procedure: adjuvant therapy
Procedure: biopsy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Procedure: quality-of-life assessment
Radiation: radiation therapy

First Posted Date: 2007-05-07

Last Posted Date: 2013-11-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 41

Registration Number: NCT00470184

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery

Not Applicable

Terminated

Conditions: Colorectal Cancer

First Posted Date: 2007-05-07

Last Posted Date: 2023-08-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT00470353

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: erlotinib hydrochloride
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

First Posted Date: 2007-05-07

Last Posted Date: 2017-02-23

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00470535

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Cancer

Interventions: Drug: carboplatin
Drug: pegylated liposomal doxorubicin hydrochloride

First Posted Date: 2007-05-07

Last Posted Date: 2014-08-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00470067

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2006-11-23

Last Posted Date: 2013-05-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 27

Registration Number: NCT00403000

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Precancerous Condition

Interventions: Drug: HPPH

First Posted Date: 2006-01-25

Last Posted Date: 2014-01-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00281736

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Phase 1

Terminated

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2005-11-24

Last Posted Date: 2013-02-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT00258258

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: pemetrexed disodium
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2005-11-04

Last Posted Date: 2017-07-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00248495

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: pegylated liposomal doxorubicin hydrochloride

First Posted Date: 2005-10-27

Last Posted Date: 2017-08-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 42

Registration Number: NCT00244985

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Fulvestrant in Treating Patients With Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-10-27

Last Posted Date: 2013-03-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00244998

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy